Aistė Štaraitė’s Post

Heart disease is the leading cause of death among women. #USFHealth Cardiologist Dr. Daniela Crousillat is actively championing better representation of women in clinical research, emphasizing the need for tailored treatments to improve women's cardiovascular health outcomes. Learn more about our efforts to enhance the recruitment and retention of women in medical research. #NWHW #womenshealth

Report out now: Global Heart Hub International Roundtable Discussion on Late, Missed and Misdiagnosis of Heart Disease in Women - https://lnkd.in/enR_D-9e    In April 2024, Global Heart Hub hosted a patient-led roundtable on late, missed and misdiagnosis of heart disease in women in Madrid, Spain, bringing together 27 participants from across 15 countries, including women with lived experience, patient organisation leaders, public health experts, researchers and clinicians.    This one-day international roundtable discussion focussed on the issues of under-representation of women in clinical trials, late, missed and misdiagnosis of heart disease in women, under-research of female-specific risk factors and heart conditions. The resulting report focusses on four priority areas: healthcare system and medical education, research, patient & public engagement and awareness, policy change and public health. These priority areas provide a roadmap for Global Heart Hub as it embarks on a journey to engage with relevant stakeholders, with the aim to improve the screening, diagnosis and treatment journey for women with cardiovascular disease.     #WomenandCVD #TakeAction #WomenandHeart  

Before #WomensHealthMonth ends, learn about the the many ways women's heart health is undervalued in the health care system, from underrepresentation in clinical trials to slower treatment in the ER: https://lnkd.in/g-mSi44y via AdvaMed #WomensHealth #healthequity

Did you know that cardiovascular disease is the leading cause of death for women globally? 🌍🫀 Yet, many clinical trials fail to account for gender-specific cardiovascular outcomes, resulting in treatments that may not fully address the unique needs of women. 🔎 Suggestion 2 out of 5 Designing and analyzing the results of clinical trials should prioritize gender-related cardiovascular endpoints that include outcomes important to women. • Women experience different symptoms and outcomes in cardiovascular events, such as heart attacks, compared to men. 💔👩⚕️ • Including endpoints that reflect these gender-specific differences can lead to more effective, tailored treatments. 🎯 • Ensuring that trials track outcomes like stroke, heart failure, and other conditions prevalent in women can save lives and close the healthcare gap. 🩺 #EqualCare #EQUALCAREnow #GenderSpecificMedicine #CardiovascularHealth #HealthcareEquality #CloseTheGap Sources: 📊 World Economic Forum: Closing the Women’s Health Gap: A $1 Trillion Opportunity to Improve Lives and Economies, INSIGHT REPORT JANUARY 2024 📄 Tamargo et al., European Heart Journal - Cardiovascular Pharmacotherapy (2017) 3, 163–182 ————————————————————— www.equal-care.org EQUAL CARE certifies medical interventions with a balanced gender representation in data and evidence. Join EQUAL CARE today and lead the health market with our certification. Together, we can set a new standard for healthcare excellence and create a future where everyone receives the care they deserve. Let’s meet: https://lnkd.in/d592b7nB

🌟 Reflecting on Health Equity in Bleeding Disorders 🌟 Last week, I had the privilege of speaking to members of the Hemophilia Alliance about a topic that is incredibly close to my heart: Health Equity. 🩸✨ Years in bleeding disorders and studies in public health has fueled my passion for addressing health inequities. We delved into what health equity means and how it impacts the journey for those living with rare diseases: 🔹 Understanding Health Equity: It's about ensuring everyone has a fair and just opportunity to attain their full health potential, regardless of social position or other socially determined circumstances. 🔹 Impact on Patient Journey: We explored how social determinants of health (SDOH) like access to education, neighborhood environment, and economic stability play a crucial role in health outcomes. We address particular challenges in bleeding disorders including awareness and diagnosis opportunities for those with Von Willebrand Disease (VWD) as well as acknowledging the limitations in care for carriers and women with mild hemophilia A. 🔹 Recommendations for improvement include increasing equitable access to genomic sequencing and expanding support for centralized and specialized rare disease care. Here, bleeding disorders have been leading the way for many years through the Hemophilia Treatment Center (HTC) model.  As well as reducing barriers to research participation and invest in accessible and culturally relevant resources for patients – two areas Takeda aims to make an difference in. Although much progress has been made in bleeding disorders and there are best practices in this community, it’s important to continue asking how we can improve health equity and how we are influencing the community. We are certainly asking ourselves this at Takeda. 🌍💙 I’d love to hear from you: How can we improve health equity in your rare disease community? #HealthEquity #RareDiseases #HemophiliaAlliance #PatientCare #SocialDeterminantsOfHealth #GenomicSequencing #HealthcareInnovation   Lindsey Colegrove Ryan Nagy Jillian Deets Katrina McGrath Jennifer Hooks Amol Luktuke

Heart disease is the leading cause of death in the U.S. But did you know that it disproportionately affects women? The CDC estimates more than 60 million women (44%) in the United States are living with heart disease. Women under 65 are twice as likely to die from a heart attack as men of the same age. And about 1 in 5 women will die from heart disease this year. Heart disease affects people of all ages. It especially affects women, who until the mid-1980s were not included in research on heart disease. Besides biological reasons, researchers have noted multiple factors for the alarming number of women who die from heart disease, especially compared to men. Research shows women are less likely to be treated for cardiovascular problems when compared to men, including being prescribed statins and receiving lifesaving treatments like heart transplants less often. And medical device design has largely centered around what works for men's bodies. A future with better health for all includes everything from better understanding the factors that contribute to heart disease, including socioeconomic factors like less access to fresh food and healthcare services, to better designing treatments for a diverse population. We're proud to be playing a small role in this shift, by helping to miniaturize medical devices so they work with different body types, and by enabling individuals to manage their own health through wireless medical devices that can take the place of regular doctor's visits to deliver treatments. More progress is needed and we're inspired by what's possible when researchers, scientists, engineers, and innovators collaborate to develop better care for underrepresented groups like women and people of color. #healthcare #patientcare #medicaldevicedesign #betterhealthforall

🚀 Exciting News: Launch of the EU SHD Coalition Task Force on Women’s Heart Health! 🚀 We are thrilled to announce the formation of the Task Force on Women’s Heart Health under the EU SHD Coalition! This initiative aims to address critical gender gaps in structural heart disease (SHD) and cardiovascular disease (CVD), and we need your expertise! 🔍 Key Focus Areas of the Task Force: 👵 👴 Gather and analyse data to showcase gender differences in structural heart disease (SHD) and cardiovascular disease (CVD). 📜 Create a detailed position paper addressing the importance of this issue. ✍ Develop a clear plan to put these policy recommendations into action. 📅 We are pleased to extend a Call for Interest till November 30th. If you're a passionate healthcare professional or advocate for women's heart health and would like to contribute to this important work, we invite you to connect with the Coalition's Secretariat. Together, we can make a significant impact! 👉 Contact us here: secretariat@structuralheartdiseasecoalition.eu #EUSHDcoalition #womenshealth #awareness #healthcare 

At Reciprocity Health, we are deeply committed to improving access and delivering better health outcomes at a lower cost. One of the areas we focus on is eye health, particularly for populations at risk, like those living with diabetes. Diabetic retinal scans are vital in preventing sight loss for diabetic patients. These screenings can detect diabetic retinopathy early, often before patients even notice any changes in their vision. Early detection and intervention are key to preserving sight and improving quality of life. We believe in incentivizing patients to prioritize their eye health. By rewarding patients for attending these essential exams, we not only encourage regular screenings but also foster a proactive approach to health management. Our behavioral economics-based campaigns are designed to ensure that at-risk patients stay on top of their eye health, ultimately leading to better outcomes.

📣 New Evidence Brief: What Works to Address Inequalities in Lipid Management ❤️ Cardiovascular disease is leading cause of inequalities in life expectancy. Addressing inequalities in lipid management priority for the NHS and part of the Core20PLUS5 approach. There’s no silver bullet for addressing inequalities in lipid management, but rather a multi-component, multi-level approach is needed. We found evidence to support the following actions: 🎯 Identification and empowerment of disadvantaged patients at risk through culturally tailored screening programmes led by community coalitions and education for primary care professionals to address implicit biases and health inequalities. 🎯 Optimisation of treatment with quality improvement interventions focusing on lifestyle changes, medication, and community health worker support for training and patient care. 🎯 Intensification of treatment to help disadvantaged patients reach cholesterol goals with structured coaching models, regular risk assessments, evidence-based therapeutic choices, patient engagement, and practitioner adherence to national guidelines. Read full evidence brief here https://lnkd.in/eH_UDCew Anna Gkiouleka, PhD, Amy Dehn Lunn Payam Torabi Jenny Blythe Prof. Bola Owolabi, MRCGP MFPH(Hon), FRSPH Helen Williams #healthinequalities

Are we really doing enough to close the gaps in kidney and heart disease care for underserved communities? At Luminary Clinical Research, our mission goes beyond just routine clinical studies. We're dedicated to advancing Renal & Cardiovascular Research in new, innovative ways. Our goal? 👉 To improve how we understand and manage kidney and heart conditions while prioritizing patient care. Our team is multidisciplinary. Scientists and clinicians collaborate to explore the root causes of conditions like: ~ High blood pressure ~ Chronic kidney disease ~ Cardiac insufficiency ~ Vascular issues We focus on improving diagnostic methods and developing groundbreaking treatments. Why? Because our aim is to enhance patient outcomes and quality of life. But that’s not all. 🚫 We’re committed to addressing disparities in healthcare access. Especially in underserved communities, we’re finding solutions to improve kidney and heart health. Through partnerships with healthcare providers, industry leaders, and advocacy groups, we translate research into real-world applications. These efforts shape public health policies and help reduce the burden of kidney and heart diseases. At Luminary, we believe in combining cutting-edge science with compassionate care. Curious about our research? Let’s connect and discuss how we’re shaping the future of kidney and heart health! #LuminaryClinicalResearch #RenalResearch #CardiovascularHealth #ClinicalResearch